The Government of Canada is supporting the development of a new cancer radiation therapy device that could lead to more precise and life-saving treatment methods.
The project has also leveraged support from two industry partners, ASG Superconductors and Paramed, which will both play an important role in facilitating the commercialization of the new technology.This invention relates to a novel investigational therapy that CEL-SCI believes has the potential to be a method for pre-sensitizing cancer with Multikine (Leukocyte Interleukin, Injection) prior to a therapeutic treatment such as chemotherapy, radiation therapy or immunotherapy. Clinical studies conducted to date on CEL-SCI’s investigational drug Multikine (Leukocyte Interleukin, Injection) indicate its potential to be able to induce cancerous cells’ entry into the cell cycle phase thereby possibly increasing their vulnerability to chemotherapy and radiation therapy. Further research is required and underway in an effort to confirm these results. In the ongoing Phase III clinical study, Multikine (Leukocyte Interleukin, Injection) is administered to patients receiving this investigational therapy ahead of surgery, radiation and chemotherapy, in advanced primary (not yet treated) head and neck cancer."We at ASG Superconductors and Paramed strongly believe that this exciting technology is one of the most promising ways to improve the treatment of tumours," said Paramed Sales Manager Antonio Toso. "Patients are our first concern and we are proud to partner with AHS to deliver this innovative system to a larger public audience."Vulcan Global Manufacturing Solutions is a leader in custom-made radiation protection products manufactured from lead, tungsten, high-density plastics and non-lead metal polymers. ISO 9001/2008 registered, Vulcan GMS is a provider of components and assemblies for some of the world's largest equipment companies. The company specializes in the medical, security, aviation and explosives industries.CEL-SCI Corporation is developing investigational products that empower immune defenses. Its lead investigational product is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also developing (and investigating) an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.A stronger West. A stronger CanadaContacts Vulcan GMS, Inc. Tom Trisco 414-645-2040 x 317 Email Contact Libby Communications Bill Libby 231-755-4111 Email ContactA federal investment of $2.5 million will support the University of Alberta, Alberta Health Services' Cross Cancer Institute and industry to develop, test and commercialize a new cancer radiation therapy technology called Magnetic Resonance Real-time Guided Radiation Therapy (MRrtgRT). In addition to federal funding, the Province of Alberta is also investing $250,000 towards the initiative, while the Alberta Cancer Foundation is contributing $2.15 million. Alberta Health Services and its industry partners, ASG Superconductors and Paramed, are contributing $1.1 million.About Vulcan GMS"At the Alberta Cancer Foundation, we promise donors progress," said Myka Osinchuk, Alberta Cancer Foundation CEO. "We are confident our substantial donor investment in this research ensures patients realize greater therapeutic value with fewer, shorter treatments. That is genuine progress."The MRrtgRT prototype will combine two existing medical devices-a magnetic resonance scanner (MRI) and a linear accelerator (LINAC)-to create a novel, human-scale integrated medical device. This device will produce high-quality, real-time 3D images with the potential to pinpoint cancer tumours more accurately while treating the tumour with radiation therapy. The device has significant potential to improve the effectiveness and precision of treatment while expanding the range of tumours that can be treated by radiation therapies.Subscribe to news releases and keep up-to-date on the latest from WD.Contacts: Donna Kinley Manager, Communications Western Economic Diversification Canada (780) 495-6892 Kathleen Range Alberta Health and Wellness (780) 427-5357 Phoebe Dey Manager of Communications Alberta Cancer Foundation (780) 643-4510 Haydon Dewes Communications Alberta Health Services (403) 918-2290 Sandra Pysklywyc Media Associate Marketing and Communications University of Alberta (780) 492-0436Federal funding is directed towards the purchase of an MRI scanner that is being advance engineered to create the full-scale MRrtgRT prototype. These costs include renovations to the vault where the prototype will be housed, engineering and construction designs, and contractors and manpower required to facilitate the construction of a full-scale MTrtgRT prototype within the Cross Cancer Institute.Website: WD is online at www.wd-deo.gc.ca ."The MR-Linac Research Project will allow the U of A's world class research team to strengthen their position as leaders in cancer research," said Dr. Lorne Babiuk, Vice-President Research. "This is a tremendous example of a partnership between different orders of government, provincial organizations, the private sector and post-secondary coming together to address the need for more research to advance the early detection and treatment of cancer."For more information, please visit www.cel-sci.com.Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, currently being developed for treatment of head and neck cancer.
Contacts: Donna Kinley Manager, Communications Western Economic Diversification Canada (780) 495-6892 Kathleen Range Alberta Health and Wellness (780) 427-5357 Phoebe Dey Manager of Communications Alberta Cancer Foundation (780) 643-4510 Haydon Dewes Communications Alberta Health Services (403) 918-2290 Sandra Pysklywyc Media Associate Marketing and Communications University of Alberta (780) 492-0436
No comments:
Post a Comment